Paroxetine (Seroxat): reminder to use the recommended dose: Message from Professor Gordon Duff, Chairman, Committee on Safety of Medicines
|Last updated 11/03/04|
I wrote to you in June, September and December to inform you of advice of the Committee on Safety of Medicines (CSM) in relation to the use of selective serotonin uptake inhibitors (SSRIs) in children and adolescents with major depressive disorder.
Since then the Expert Working Group of the CSM has reviewed clinical trial data on the use of paroxetine (Seroxat) in adults.
A review of these data has confirmed that, as stated in the summary of product characteristics, 20 mg is the recommended daily dose in adults for the treatment of depression, social anxiety disorder (SAD), generalised anxiety disorder (GAD) and post traumatic stress disorder (PTSD). 40 mg is the recommended daily dose in adults for the treatment of obsessive compulsive disorder and panic disorder. There is no evidence from clinical trials that increasing the dose above the recommended dose increases efficacy in the treatment of depression, SAD, GAD, PTSD and panic disorder.
General prescribing advice for paroxetine:
1. Paroxetine should be prescribed at the recommended dose.
2. If your patient is being successfully treated at higher than the recommended dose, then this dose should be continued to the end of the planned course of treatment.
3. If your patient is being treated at higher than the recommended dose and is not doing well then a change of treatment should be considered.
4. There is evidence that attempts to escalate the dose rapidly are associated with an increased incidence of adverse events.
5. The adverse events that occur soon after starting therapy may be difficult to distinguish from the underlying condition. There is evidence that increasing the dose in this situation may be detrimental.
6. Patients taking paroxetine should not stop treatment suddenly. Any cessation of treatment should proceed by a gradual downward titration.
Please report any suspected adverse reactions to paroxetine via the Yellow Card reporting scheme to the CSM/ MHRA.
Should you require any additional information, please telephone 020 7084 2000 at the MHRA.
Professor Gordon Duff
If you have any enquiries, please contact the MHRA (medicines) on 020-7084 2000 or e-mail mailto:firstname.lastname@example.org
|Important safety messages||
|questions and answers|